Gene Therapies: Building sustainable commercial strategies

Gene therapy companies are part of a scientific vanguard — but must blaze new commercial pathways as well. Real Endpoints is bringing together a select group of senior gene therapy executives to discuss, in an informal resort setting and under Chatham House rules, future best practices in the commercialization of this utterly novel class of therapies. In case studies, group sessions, and one-on-one conversations, this meeting will delve into issues such as the challenges of launching one-time cures in markets dominated by chronic therapies; making the cost-effectiveness case in a world of short-term insurance models; and the latest in innovative contracting approaches.